Clinical Trials Logo

Relapsed Adult AML clinical trials

View clinical trials related to Relapsed Adult AML.

Filter by:

NCT ID: NCT04310592 Recruiting - Leukemia Clinical Trials

Natural Killer Cell (CYNK-001) Infusions in Adults With AML

CYNK001AML01
Start date: March 12, 2020
Phase: Phase 1
Study type: Interventional

This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.

NCT ID: NCT04139434 Active, not recruiting - Relapse Clinical Trials

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Start date: July 6, 2020
Phase: Phase 1
Study type: Interventional

A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

NCT ID: NCT03932318 Withdrawn - Clinical trials for Acute Myeloid Leukemia

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Start date: March 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 when given in combination with venetoclax and azacitidine for patients with CD33 positive AML. (Phase I portion) 2. To assess the percentage of patients with CR, CRh, CRi, MLFS or Overall Response (CR + CRh + CRi + MLFS), up to 6 months after the start of treatment without receiving other AML therapies.. (Phase 2 portion)

NCT ID: NCT03867682 Recruiting - Clinical trials for Acute Myeloid Leukemia

Venetoclax and Lintuzumab-Ac225 in AML Patients

Start date: January 15, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion) 2. To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to 6 months after the start of treatment without receiving other AML therapies. (Phase 2 portion)

NCT ID: NCT03848754 Completed - Relapsed Adult AML Clinical Trials

Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Start date: May 24, 2019
Phase: Phase 1
Study type: Interventional

This is a prospective, single-center phase 1 clinical study aimed at determining the maximum-tolerated dose and safety of the combination of gemtuzumab ozogamicin (GO) and pracinostat (P) in patients with relapsed/refractory acute myeloid leukemia.

NCT ID: NCT03245424 Approved for marketing - Clinical trials for Acute Myeloid Leukemia

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Start date: n/a
Phase:
Study type: Expanded Access

To provide access to ivosidenib monotherapy to patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation.

NCT ID: NCT03091933 Recruiting - Clinical trials for Relapsed Multiple Myeloma

Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)

GLIDE
Start date: February 6, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety of infusing an anti-MiHA T cell line in patients suffering from an hematologic malignancy that has relapsed following hematopoietic stem cell transplantation from a matched donor.